CLINICAL TRIAL / NCT03729115

Inclusion Criteria: - Known BRCA1 or BRCA2, TP53, PALB2, PTEN, CDH1 and STK11 carrier. Women with pathogenic mutations in any other cancer susceptibility genes are eligible only if they also have a high PRS. OR - With life time risk of 30% or higher, based on Polygenic Risk Score that integrates genetic and non-genetic factors OR - 5-years risk ≥ 6% for women 40-64 OR - 5-years risk ≥ 6% for women 65+ AND breast density C or D AND a lifetime risk >= 20% (BCSC+PRS LTR or Tyrer-Cuzick LTR) OR - Patients with history of chest wall radiation received before age 35. OR - To promote health equity, women of African Ancestry < 45 years with at least one 1st or 2nd degree relative with breast or ovarian cancer are eligible because PRS Scores are not currently reported for AA women. - Must be at least 25 years old. - Willing to travel to participating site for imaging studies as well as any necessary follow-up procedures. - Be able to give informed consent. - Patients with prior history of breast or ovarian cancer are eligible if they have completed all active treatments and are cancer free for two years. Exclusion Criteria - Undergoing active cancer treatment at the time of enrollment. - Current pregnancy or plans for pregnancy within two years of enrollment. - Presence of a pacemaker or any other metallic foreign object in their body that interferes with an MRI. - Breast surgery within two weeks of study entry. - Women with history of bilateral mastectomy are not eligible - History of kidney disease or abnormal kidney function. - History of dye allergy unless it can be mediated with antihistamines and/or steroids - Women can be taking hormone replacement therapy, tamoxifen, raloxifene, aromatase inhibitors, Parp Inhibitors as adjuvant therapy or participating in a chemoprevention trial.